DDInter1881 DDInter557
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylergometrine
Methylergometrine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylergometrine
Methylergometrine {u} (Compound) palliates {v} (Disease) migraine
migraine {u} (Disease) is palliated by {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} (Compound) causes {v} (Side Effect) Depressed level of consciousness
Depressed level of consciousness {u} (Side Effect) is caused by {v} (Compound) Dihydroergotamine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) upregulates {v} (Gene) TNFRSF21
TNFRSF21 {u} (Gene) is downregulated by {v} (Compound) Dihydroergotamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Dihydroergotamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dihydroergotamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dihydroergotamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) palliates migraine (Disease) and migraine (Disease) is palliated by Dihydroergotamine (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene (Compound) causes Depressed level of consciousness (Side Effect) and Depressed level of consciousness (Side Effect) is caused by Dihydroergotamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) upregulates TNFRSF21 (Gene) and TNFRSF21 (Gene) is downregulated by Dihydroergotamine (Compound)